https://www.selleckchem.com/products/dmog.html
3 (2.3-12.5), p0.001). Inhibitors are and will continue to be the most significant complication of haemophilia treatment with factor concentrates. This is particularly true for haemophilia A. In our cohort, we were able to show that the treatment regimen used during first 50EDs influenced significantly the inhibitor risk, but the class of the factor concentrate did not play an important role. Real world data will remain one of the important resources for improving our knowledge of haemophilia. Inhibitors are and will continue to be the
Like
Comment
Share
